Recent insider trading activity from Cross John Harry III, including buys and sells reported to the SEC.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 7, 2025 | Senti Biosciences, Inc. | $SNTI | Cross John Harry III | Chief Financial Officer | A | Stock Option (Right to Buy) | 174200 | $0.00 | 174,200.0000 | 4,829,035 | 9999.99% | 3.61% |
| Dec. 11, 2023 | Sonnet BioTherapeutics Holdings, Inc. | $SONN | Cross John Harry III | Chief Financial Officer | A | Common Stock | 1452 | $0.00 | 1,588.0000 | 0 | 47.76% | 0.00% |